Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). (Q54134070)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). |
scientific article |
Statements
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). (English)
0 references
Swiss Group for Clinical Cancer Research (SAKK)
Roger von Moos
Dieter Koeberle
Sabina Schacher
Ralph C Winterhalder
Arnaud Roth
György Bodoky
Panagiotis Samaras
Martin D Berger
Daniel Rauch
Piercarlo Saletti
Ludwig Plasswilm
Daniel Zwahlen
Urs R Meier
Pu Yan
Paola Izzo
Daniela Bärtschi
Kathrin Zaugg
11 December 2017
89
82-89